Table 3. Characteristics of studies on the effect of AT-II on the T/N ratio in patients with hepatic malignancies.
| Author (year) | Study sizeN patients(tumors) | Tumor type(N patients) | AT-IIdose | Radioactivetracer | T/Nmeasurement |
| Sasaki et al. [25] | 9 (14) | HCC (7) | 10 μg/min for 3–4 min | 81mKr solution | RA measurement with scintillation camera during infusion |
| (1985) | CRLM (2) | ||||
| Goldberg et al. 1 [33] | 9 | CRLM (8) | 10 μg/min for 100 sec | 131I before and | Biopsies of tumor and non-tumor. RA measured with |
| (1991) | UP (1) | 99mTc after AT-II | scintillation camera | ||
| Goldberg et al. 2 [34] | 9 (48) | CRLM (9) | 10 μg/min for 100 sec | 99mTc MSA | SPECT after albumin colloid injection and HAPS |
| (1991) | |||||
| Burke et al. [19] | 9 (11) | CRLM (9) | 5 μg/min for 45 min | 62Cu-PTSM | PET |
| (2001) | |||||
| Ishikawa et al. [36] | 35 | PCLM (35) | 5 μg/min for 10 sec | None | CT contrast enhancement measurement |
| (2007) |
Abbreviations: HCC = Hepatocellular Carcinoma. CRLM = Colorectal Liver Metastases. UP = Metastases of an Unknown Primary. PCLM = Pancreatic Cancer Liver Metastases. NA = Not Available. RA = radioactivity. SPECT = Single-Photon Emission Computed Tomography. HAPS = Hepatic Arterial Perfusion Scintigraphy. PET = Positron Emission Tomography. 81mKr = Krypton-81m. 131I = Iodine-131. 99mTc MSA = Radiolabeled albumin microspheres. 62Cu-PTSM = copper-pyruvaldehyde-bis (N4-methylthiosemicarbazone).